Hopp til hovedinnhold

Parkinsons sykdom

Sist oppdatert: Sist revidert:
Sist revidert av:

Se oversiktsartikkel (2015) 1 og (2020) 2.

Parkinsons sykdom er en kronisk nevrodegenerativ sykdom som kjennetegnes primært ved nevrontap i substantia nigra og dertil relatert dopaminmangel i basalganglier. Dette fører til utvikling av parkinsonisme som responderer på dopaminerg behandling. Sykdomsprosessen rammer i tillegg andre, ikke-dopaminerge deler av nervesystemet, spesielt ved lengre tids sykdom. Dette er årsak til at ikke-motoriske symptomer forekommer hyppig. Årsaken til Parkinsons sykdom er i de aller fleste tilfeller ukjent. Sykdommen debuterer oftest etter 50 år og rammer menn oftere enn kvinner.

Nasjonalt kompetansesenter for bevegelsesforstyrrelser 

  1. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015 Aug 29;386(9996):896-912. pmid:25904081 PubMed  
  2. Armstrong MJ Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. . JAMA 2020 . pmid:32044947 PubMed  
  3. Ongre SO, Larsen JP, Tysnes OB, Herlofson K.. Fatigue in early Parkinson's disease: the Norwegian ParkWest study. PubMed Commons Reader comments Trending articles Publication dates 5 years 10 years Custom range. Species Humans Other Animals Clear all Show additional filters Format: Summary Sort by: Most Recent Send to Search results Items: 2 Select item 27670392 1. Fatigue in early Parkinson's disease: the Norwegian ParkWest study. Ongre SO, Larsen JP, Tysnes OB, Herlofson K. Eur J Neurol. 2016 Sep 26. pmid:27670392 PubMed  
  4. Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Santangelo G, Pellecchia MT, Barone P. The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study. Eur J Neurol. 2016 Nov;23(11):1673-1679 . pmid:27435448 PubMed  
  5. Srivanitchapoom P, Hallett M. Camptocormia in Parkinson's disease: definition, epidemiology, pathogenesis and treatment modalities. J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):75-85. pmid:25896683 PubMed  
  6. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson's disease.. Mov Disord. 2015; Oct;30(12): 1591-601. pmid:26474316 PubMed  
  7. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M. EFNS/MDS-ES/ENS corrected recommendations for the diagnosis of Parkinson's disease. Eur J Neurol 2013; 20: 16-34. PMID: 23279440 PubMed  
  8. Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D; Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology. 2014 May 20;82(20):1791-7. pmid:24759846 PubMed  
  9. Erro R, Schneider SA, Stamelou M, Quinn NP, Bhatia KP.. What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies. J Neurol Neurosurg Psychiatry 2016; Mar;87(3):319-23. pmid: 25991401 PubMed  
  10. Ali K, Morris HR. Parkinson's disease: chameleons and mimics. Pract Neurol 2015; 15: 14-25. pmid:25253895 PubMed  
  11. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. JAMA Neurol. 2015 Aug;72(8):863-73 . pmid:26076039 PubMed  
  12. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N; Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129-70. PMID: 19025984 PubMed  
  13. Dietrichs E, Odin P. Algorithms for the treatment of motor problems in Parkinson's disease. Acta Neurol Scand. 2017 Nov;136(5):378-385. PMID: 28133726 PubMed  
  14. Ståhle A, Yrkesföreningar för Fysisk A. FYSS 2017: fysisk aktivitet i sjukdomsprevention och sjukdomsbehandling. Stockholm: Läkartidningen förlag, 2016.
  15. Keus, S., Munnecke, M., Graziano, M., & et.al. European Physiotherapy Guideline for Parkinson's disease. 2014; KNGF/ParkinsonNet, the Nederlands. Retrieved from http://parkinsonnet.info/guidelines
  16. Hiorth, Y. H., Borg, K., & Nilsson, M. H. (2016). Fysisk aktivitet vid Parkinsons sjukdom. In Yrkesföreningar för Fysisk Aktivitet (YFA) (Ed.), FYSS 2017: fysisk aktivitet i sjukdomsprevention och sjukdomsbehandling (pp. 521-531).
  17. Kwok JYY, Kwan JCY, Auyeung M, Mok VCT, Lau CKY, Choi KC, Chan HYL. Effects of Mindfulness Yoga vs Stretching and Resistance Training Exercises on Anxiety and Depression for People With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2019 Jul 1;76(7):755-763. PMID: 30958514 PubMed  
  18. Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schüpbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20: 5-15. PMID: 23279439 PubMed  
  19. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014; Aug;85. pmid:24434037 PubMed  
  20. Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O'Brien MD, Silsbee H, Gronseth G, Lang AE; Guideline Subcommittee of the AAN. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 Nov 16;97(20):942-957. doi: 10.1212/WNL.0000000000012868. PMID: 34782410; PMCID: PMC8672433.
  21. Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, van Laar T, Tissingh G, Munts AG, Deuschl G, Lang AE, Dijkgraaf MGW, de Haan RJ, de Bie RMA; LEAP Study Group. Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. N Engl J Med. 2019 Jan 24;380(4):315-324. PMID: 30673543 PubMed  
  22. Hu XW, Qin SM, Li D, Hu LF, Liu CF. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis. Acta Neurol Scand. 2013 Aug;128(2):73-82. pmid: 23432663 PubMed  
  23. Barthel C, Nonnekes J, van Helvert M, Haan R, Janssen A, Delval A, Weerdesteyn V, Debû B, van Wezel R, Bloem BR, Ferraye MU. The laser shoes: A new ambulatory device to alleviate freezing of gait in Parkinson disease. Neurology. 2018 Jan 9;90(2):e164-e171. doi: 10.1212/WNL.0000000000004795. Epub 2017 Dec 20. PMID: 29263221 PubMed  
  24. Okuma Y. Practical approach to freezing of gait in Parkinson's disease. Pract Neurol 2014; Aug;14(4): 222-30. pmid:24532673 PubMed  
  25. Nonnekes J, Snijders AH, Nutt JG, Deuschl G, Giladi N, Bloem BR. Freezing of gait: a practical approach to management. Lancet Neurol. 2015 Jul;14(7):768-78. pmid:26018593 PubMed  
  26. Barone P1, Santangelo G2, Amboni M3, Pellecchia MT1, Vitale C4.. Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment.. Lancet Neurol. 2016 Sep;15(10):1063-74. pmid:27571158 PubMed  
  27. Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE; PD MED Collaborative Group. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial. JAMA Neurol. 2022 Feb 1;79(2):131-140. doi: 10.1001/jamaneurol.2021.4736. PMID: 34962574; PMCID: PMC8715387.
  28. Worth PF. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies. Pract Neurol. 2013; 13: 140-52. PMID: 23487815 PubMed  
  29. Nysveen I, Jusufovic M, Luth SM, Gundersen G, Skogseid IM. En mann i 50-årene med økende motoriske svingninger, søvnvansker og mental endring.TNLF nr 14 2020
  30. Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin PLA. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018 Dec;34(12):2063-2073. doi: 10.1080/03007995.2018.1502165. Epub 2018 Aug 20. PMID: 30016901.
  31. Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, Antonini A, Rascol O, Poewe W; National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015 Oct;21(10):1133-44. pmid:26233582 PubMed  
  32. Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nat Rev Neurol. 2019 Apr;15(4):234-242. PMID: 30778210 PubMed  
  33. Lilleeng B, Gjerstad M, Baardsen R, Dalen I, Larsen JP. The long-term development of non-motor problems after STN-DBS. Acta Neurol Scand. 2015 Oct;132(4):251-8. pmid:25752590 PubMed  
  34. Martinez-Fernandez R, Pelissier P, Quesada JL, Klinger H, Lhommée E, Schmitt E, Fraix V, Chabardes S, Mertens P, Castrioto A, Kistner A, Broussolle E, Pollak P, Thobois S, Krack P. Postoperative apathy can neutralise benefits in quality of life after subthalamic stimulation for Parkinson's disease.. Martinez-Fernandez R, Pelissier P, Quesada JL, Klinger H, Lhommée E, Schmitt E, Fraix V, Chabardes S, Mertens P, Castrioto A, Kistner A, Broussolle E, Pollak P, Thobois S, Krack P. 2016; Mar;87(3): 311-8. pmid:25934016 PubMed  
  35. Sauerbier A, Loehrer P, Jost ST, Heil S, Petry-Schmelzer JN, Herberg J, Bachon P, Aloui S, Gronostay A, Klingelhoefer L, Baldermann JC, Huys D, Nimsky C, Barbe MT, Fink GR, Martinez-Martin P, Ray Chaudhuri K, Visser-Vandewalle V, Timmermann L, Weintraub D, Dafsari HS; EUROPAR and the International Parkinson and Movement Disorders Society Non-Motor Parkinson's Disease Study Group. Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry. 2021 Sep 11:jnnp-2021-326131. PMID: 34510000. PubMed  
  36. Toft M, Lilleeng B, Ramm-Pettersen J, Røste GK, Pedersen L, Skogseid IM, Dietrichs E. Behandling av bevegelsesforstyrrelser med dyp hjernestimulering. Tidsskr Nor Laegeforen 2008; 128: 1972-6. Tidsskrift for Den norske legeforening  
  37. de Chazeron I, Pereira B, Chereau-Boudet I, Durif F, Lemaire JJ, Brousse G, Ulla M, Derost P, Debilly B, Llorca PM. Impact of localisation of deep brain stimulation electrodes on motor and neurobehavioural outcomes in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2015 Aug 21. pmid:26296870 PubMed  
  38. Olanow CW, Kieburtz K, Odin P, et al; LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014; Feb;13(2):: 141-9. pmid:24361112 PubMed  
  39. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26 Suppl 3: 42-80. PMID: 22021174 PubMed  
  40. Pigott K, Rick J, Xie SX, Hurtig H, Chen-Plotkin A, Duda JE, Morley JF, Chahine LM, Dahodwala N, Akhtar RS, Siderowf A, Trojanowski JQ, Weintraub D. Longitudinal study of normal cognition in Parkinson disease. Neurology. 2015 Oct 13;85(15):1276-82. pmid: 26362285 PubMed  
  41. Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. J Neurol Neurosurg Psychiatry. 2014. pmid:25224676 PubMed  
  42. Leung IH, Walton CC, Hallock H, Lewis SJ, Valenzuela M, Lampit A. Cognitive training in Parkinson disease: A systematic review and meta-analysis. Neurology. 2015 Nov 24;85(21):1843-51. pmid:26519540 PubMed  
  43. Pagano G, Rengo G, Pasqualetti G, Femminella GD, Monzani F, Ferrara N, Tagliati M. Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):767-73. pmid:25224676 PubMed  
  44. Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2014. pmid:24828899 PubMed  
  45. Larsen JP, Dalen I, Pedersen KF, Tysnes OB. The natural history of depressive symptoms in patients with incident Parkinson's disease: a prospective cohort study. J Neurol. 2017 Dec;264(12):2401-2408. PMID: 29032408 PubMed  
  46. Gratwicke J, Zrinzo L, Kahan J, Peters A, Beigi M, Akram H, Hyam J, Oswal A, Day B, Mancini L, Thornton J, Yousry T, Limousin P, Hariz M, Jahanshahi M, Foltynie T. Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2017 Dec 18. PMID: 29255885 PubMed  
  47. Fan JQ, Lu WJ, Tan WQ, Liu X, Wang YT, Wang NB, Zhuang LX. Effectiveness of Acupuncture for Anxiety Among Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Netw Open. 2022 Sep 1;5(9):e2232133. doi: 10.1001/jamanetworkopen.2022.32133. PMID: 36129711 PubMed  
  48. Beze S, Castellani L, Pereira B, Chiambaretta F, Durif F, Marques A. Two-year longitudinal follow-up of visual illusions and hallucinations in Parkinson's disease. J Neurol. 2022 Aug;269(8):4546-4554. doi: 10.1007/s00415-022-11074-2. Epub 2022 Mar 16. PMID: 35296961. PubMed  
  49. Vardy ER, Teodorczuk A, Yarnall AJ. Review of delirium in patients with Parkinson's disease. J Neurol. 2015 Nov;262(11):2401-10 . pmid:25957635 PubMed  
  50. Baig F, Kelly MJ, Lawton MA, Ruffmann C, Rolinski M, Klein JC, Barber T, Lo C, Ben-Shlomo Y, Okai D, Hu MT. Impulse control disorders in Parkinson disease and RBD: A longitudinal study of severity. Neurology 2019. pmid:31311842 PubMed  
  51. Romagnolo A, Zibetti M, Merola A, Canova D, Sarchioto M, Montanaro E, Artusi CA, Vallelonga F, Maule S, Lopiano L. Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study. J Neurol. 2019 Jan;266(1):85-91. PMID: 30382389 PubMed  
  52. Asahina M, Vichayanrat E, Low DA, Iodice V, Mathias CJ. Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology. J Neurol Neurosurg Psychiatry 2013; 84: 674-80. PMID: 22942216 PubMed  
  53. Espay AJ, LeWitt PA, Hauser RA, et al. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.. Lancet Neurol. 2016 Aug;15(9):954-66. pmid:27478953 PubMed  
  54. Veazie S, Peterson K, Ansari Y, Chung KA, Gibbons CH, Raj SR, Helfand M. Fludrocortisone for orthostatic hypotension. Cochrane Database Syst Rev. 2021 May 17;5(5):CD012868. doi: 10.1002/14651858.CD012868.pub2. PMID: 34000076; PMCID: PMC8128337. The Cochrane Library  
  55. Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2015 Jun;14(6):625-39. pmid:25987282 PubMed  
  56. Gómez-Caravaca MT1, Cáceres-Redondo MT, Huertas-Fernández I, Vargas-González L, Carrillo F, Carballo M, Mir P.. The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders. Neurol Sci. 2014. pmid:25238916 PubMed  
  57. Møller E, Daugaard D, Holm O, Winge K, Bardow A, Lykkeaa J, Belhage B, Bakke M. Repeated treatments of drooling with botulinum toxin B in neurology. Acta Neurol Scand 2015; 131: 51-7. pmid:25270197 PubMed  
  58. Cosentino G, Avenali M, Schindler A, Pizzorni N, Montomoli C, Abbruzzese G, Antonini A, Barbiera F, Benazzo M, Benarroch EE, Bertino G, Cereda E, Clavè P, Cortelli P, Eleopra R, Ferrari C, Hamdy S, Huckabee ML, Lopiano L, Marchese Ragona R, Masiero S, Michou E, Occhini A, Pacchetti C, Pfeiffer RF, Restivo DA, Rondanelli M, Ruoppolo G, Sandrini G, Schapira AHV, Stocchi F, Tolosa E, Valentino F, Zamboni M, Zangaglia R, Zappia M, Tassorelli C, Alfonsi E. A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. J Neurol. 2021 Aug 21. PMID: 34417870. PubMed  
  59. De Cock VC, Dodet P, Leu-Semenescu S, Aerts C, Castelnovo G, Abril B, Drapier S, Olivet H, Corbillé AG, Leclair-Visonneau L, Sallansonnet-Froment M, Lebouteux M, Anheim M, Ruppert E, Vitello N, Eusebio A, Lambert I, Marques A, Fantini ML, Devos D, Monaca C, Benard-Serre N, Lacombe S, Vidailhet M, Arnulf I, Doulazmi M, Roze E. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol. 2022 May;21(5):428-437. doi: 10.1016/S1474-4422(22)00085-0. PMID: 35429481. PubMed  
  60. Büchele F, Hackius M, Schreglmann SR, Omlor W, Werth E, Maric A, Imbach LL, Hägele-Link S, Waldvogel D, Baumann CR. Sodium Oxybate for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Jan 1;75(1):114-118. PMID: 29114733 PubMed  
  61. Stanton BR, Carson A. Apathy: a practical guide for neurologists. Pract Neurol. 2016 Feb;16(1):42-7. pmid:26502729 PubMed  
  62. Devos D, Moreau C, Maltête D, Lefaucheur R, Kreisler A, Eusebio A, Defer G, Ouk T, Azulay JP, Krystkowiak P, Witjas T, Delliaux M, Destée A, Duhamel A, Bordet R, Defebvre L, Dujardin K. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.. J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):668-74. 2014; Jun;85(6): 668-74. pmid:24218528 PubMed  
  63. Elbers RG, Verhoef J, van Wegen EE, Berendse HW, Kwakkel G. Interventions for fatigue in Parkinson's disease. Cochrane Database Syst Rev. 2015 Oct 8;10:CD010925. pmid:26447539 PubMed  
  64. Inzelberg R, Flash S, Friedman E, Azizi E. Cutaneous malignant melanoma and Parkinson disease: Common pathways? . Ann Neurol 2016. pmid:27761938 PubMed  
  65. Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton JP, Wolf JE Jr; North American Parkinson's and Melanoma Survey Investigators. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol. 2010 Mar;67(3):347-52. pmid:20212233 PubMed  
  66. Dalvin LA, Damento GM, Yawn BP, Abbott BA, Hodge DO, Pulido JS. . Parkinson Disease and Melanoma: Confirming and Reexamining an Association. Mayo Clin Proc . 2017 . pmid:28688464 PubMed  
  67. Wu CK, Hohler AD. Management of orthostatic hypotension in patients with Parkinson's disease. Pract Neurol 2015; 15: 100-104. pmid:25489118 PubMed  
  • Åse Mygland, spesialist i nevrologi, professor dr med
  • Unn Ljøstad, spesialist i nevrologi, professor PhD
  • Espen Dietrichs, spesialist i nevrologi, professor dr med
  • Guido Alves, spesialist i nevrologi, professor PhD